Gordon M. Binder - 15 May 2024 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Reporting relationship: Director
Issuer ticker: HUMA
Reported as of: 15 May 2024
Net transaction value: +$667,500
SEC form: 4
Accepted by SEC: 15 May 2024, 19:24:07 UTC
Prior SEC filing: 16 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Gordon M. Binder by Dale A. Sander as Attorney-in-Fact

Key filing fact

Gordon M. Binder filed Form 4 for Humacyte, Inc. (HUMA) on 15 May 2024.

Key facts

This page summarizes Gordon M. Binder's Form 4 filing for Humacyte, Inc. (HUMA).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 15 May 2024, 19:24.

Change

Previous filing in this sequence was filed on 16 Jun 2023.
Current net transaction value: +$667,500.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HUMA transaction

Common Stock

Purchase

Transaction value: $328,500
Shares: +50,000
Change %
Price: $6.57
Shares after: 50,000
Date: 15 May 2024
Ownership: By the Binder Trust dated 15 July 2003
Footnotes: F1

HUMA transaction

Common Stock

Purchase

Transaction value: $339,000
Shares: +50,000
Change %: +45%
Price: $6.78
Shares after: 160,000
Date: 15 May 2024
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $6.44 to $6.59. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Footnote F2

The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $6.64 to $6.96. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.